KKR's $5.7B Integer Acquisition Clears Antitrust Hurdle

Event summary

Integer Holdings (NYSE: ITGR) received early termination of the HSR waiting period for its $5.7B acquisition by KKR.
The deal, announced August 3, 2026, values Integer at $127 per share in cash.
Special stockholder meeting set for October 21, 2026, to approve the transaction.
Transaction expected to close by year-end, pending stockholder and regulatory approvals.

The big picture

KKR's acquisition of Integer, a leading medical device contract manufacturer, underscores private equity's continued appetite for scaling up specialized healthcare services. The $5.7B deal reflects the strategic value of Integer's engineering and manufacturing capabilities in the cardio, neuromodulation, and cardiac rhythm management markets. The early HSR clearance suggests minimal antitrust concerns, but the transaction's success hinges on securing stockholder approval and navigating potential integration challenges.

What we're watching

Regulatory Approvals: Whether remaining regulatory approvals will proceed smoothly ahead of the year-end closing deadline.
Stockholder Vote: The likelihood of stockholder approval given the unanimous recommendation from Integer's board.
Integration Strategy: How KKR plans to integrate Integer's operations, particularly its Greatbatch Medical and Lake Region Medical brands.